JP2006232790A - Atオリゴヌクレオチドを有効成分とする免疫応答増強性薬剤及び食品組成物 - Google Patents
Atオリゴヌクレオチドを有効成分とする免疫応答増強性薬剤及び食品組成物 Download PDFInfo
- Publication number
- JP2006232790A JP2006232790A JP2005053998A JP2005053998A JP2006232790A JP 2006232790 A JP2006232790 A JP 2006232790A JP 2005053998 A JP2005053998 A JP 2005053998A JP 2005053998 A JP2005053998 A JP 2005053998A JP 2006232790 A JP2006232790 A JP 2006232790A
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- atttttac
- activity
- active ingredient
- food composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 114
- 235000013305 food Nutrition 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 239000004480 active ingredient Substances 0.000 title claims abstract description 29
- 230000028993 immune response Effects 0.000 claims abstract description 37
- 230000000694 effects Effects 0.000 claims abstract description 36
- 102000003945 NF-kappa B Human genes 0.000 claims abstract description 30
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 30
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 29
- 102000002689 Toll-like receptor Human genes 0.000 claims abstract description 25
- 108020000411 Toll-like receptor Proteins 0.000 claims abstract description 25
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims abstract description 19
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims abstract description 19
- 241000186606 Lactobacillus gasseri Species 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims description 36
- 230000002103 transcriptional effect Effects 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 230000001707 blastogenic effect Effects 0.000 claims description 13
- 230000002708 enhancing effect Effects 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 abstract description 35
- 108020004414 DNA Proteins 0.000 abstract description 20
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 18
- 238000012360 testing method Methods 0.000 abstract description 13
- 230000000968 intestinal effect Effects 0.000 abstract description 10
- 241000282898 Sus scrofa Species 0.000 abstract description 7
- 210000001986 peyer's patch Anatomy 0.000 abstract description 7
- 230000001404 mediated effect Effects 0.000 abstract description 6
- 210000004989 spleen cell Anatomy 0.000 abstract description 6
- 230000035584 blastogenesis Effects 0.000 abstract description 4
- 241000590002 Helicobacter pylori Species 0.000 abstract description 3
- 230000004913 activation Effects 0.000 abstract description 3
- 229940037467 helicobacter pylori Drugs 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000005758 transcription activity Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 201000006747 infectious mononucleosis Diseases 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 28
- 238000000034 method Methods 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 15
- 239000004310 lactic acid Substances 0.000 description 14
- 235000014655 lactic acid Nutrition 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000003716 rejuvenation Effects 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 210000000987 immune system Anatomy 0.000 description 10
- 239000000427 antigen Substances 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 244000052769 pathogen Species 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000003308 immunostimulating effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 108010046377 Whey Proteins Proteins 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 241001662087 Lactobacillus gasseri ATCC 33323 = JCM 1131 Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 description 3
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100024817 TNF receptor-associated factor 6 Human genes 0.000 description 2
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- -1 add pH adjusters Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ODDDVFDZBGTKDX-VPCXQMTMSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O ODDDVFDZBGTKDX-VPCXQMTMSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Chemical group CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 101100481579 Mus musculus Tlr11 gene Proteins 0.000 description 1
- 101100481580 Mus musculus Tlr12 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 102000008125 NF-kappa B p52 Subunit Human genes 0.000 description 1
- 108010074852 NF-kappa B p52 Subunit Proteins 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 101150038509 TLR9 gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Chemical group 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Chemical group 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical group OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001746 carotenes Chemical group 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000047410 human NFKB1 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Chemical group CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Chemical group O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Chemical group 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Chemical group 0.000 description 1
- 150000003710 vitamin D derivatives Chemical group 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Chemical group 0.000 description 1
- 150000003721 vitamin K derivatives Chemical group 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
【解決手段】ピロリ菌の増殖抑制効果を有するL.gasseri OLL2716(LG21)株の8塩基からなる免疫応答増強性のある新規なnonCpG配列(AT5AC-L)に含まれる特徴的なコア配列(5'-ATTTTTAC-3')をゲノムDNA中に385種類の配列を発見した。化学合成した上記 ATオリゴヌクレオチドのリンパ球幼若化活性試験を指標に解析した。標的細胞として、ブタ腸管パイエル板細胞、ブタ脾臓細胞およびヒト末梢血単核球を用いた。さらに、ブタToll様受容体9(TLR9)強制発現細胞株(トランスフェクタント)を用いたNF-κB転写活性試験を行い、最終的にTLR9を介する活性の強い新規なオリゴヌクレオチド10種を見出した。
【選択図】なし
Description
A.C. Brown, A. Valiere: Nutr. Clin. Care., 7, 56 (2004) H. S. Gill, F. Guarner: Postgrad. Med. J., 80, 516 (2004) S.J. Cunningham-Rundles: Nutr. Health. Aging., 8, 20 (2004) O. Vaarala: Clin Exp Allergy., 33, 1634 (2003) E. Pohjavuori, M. Viljanen, R. Korpela, M. Kuitunen, M. Tiittanen, O. Vaarala, E. Savilahti: J. Allergy. Clin. Immunol., 114, 131 (2004) P. Kidd. Altern: Med. Rev., 8, 223 (2003) R. Clancy: FEMS Immunol Med Microbiol., 7, 403 (2005) K. Takeda, S. Akira: J. Dermatol. Sci., 34, 73 (2004) H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, S. Akira: Nature., 408, 740 (2000) T. Shirakawa, T. Enomoto, S. Shimazu, J. M. Hopkin: Science., 275, 77 (1997) G. J. Prud'homme: J. Gene. Med., in press. R. J. Ulevitch: Nat. Rev. Immunol.,4, 512 (2004) R. K. Ahmed, G. Biberfeld, R. Thorstensson: Mol. Immunol., 42, 251 (2005) D. M. Klinman: Expert. Opin. Biol. Ther., 4, 937, (2004) H. Kitazawa, S. Ueha, S. Itoh, H. Watanabe, K. Konno, Y. Kawai, T. Saito, T. Itoh, T. Yamaguchi: Int J Food Microbiol., 65, 149 (2001) H. Kitazawa, H. Watanabe, T. Shimosato, Y. Kawai, T. Itoh, T. Saito: Int. J. Food. Microbiol., 85, 11 (2003) ID. Ilieve, H. Kitazawa, T. Shimosato, S. Katoh, H. Morita, F. He, M. Hosoda, T. Saito: Cell. Microbiol., in press. T. Shimosato, H. Kitazawa, S. Katoh, Y. Tomioka, R. Karima, S. Ueha, Y. Kawai, T. Hishinuma, K. Matsushima, T. Saito: Biochem. Biophys. Acta., 1627, 56 (2003)
(1)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、免疫応答を増強する薬剤。
(2)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、リンパ球幼若化活性を増強する薬剤。
(3)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、NF-κB転写活性を増強する薬剤。
(4)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、Toll様受容体を介する活性を増強する薬剤。
(5)Toll様受容体がToll様受容体9である、(4)に記載の薬剤。
(6)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドがLactobacillus gasseri OLL2716由来のオリゴヌクレオチドである、(1)〜(5)のいずれかに記載の薬剤。
(7)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドが、配列番号:1〜28のいずれかに記載の配列からなる、(1)〜(6)のいずれかに記載の薬剤
(8)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドが、配列番号:1、2、7、9、11、15、21、22、24、または26のいずれかに記載の配列からなる、(1)〜(6)のいずれかに記載の薬剤。
(9)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、免疫応答を増強する食品組成物。
(10)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、リンパ球幼若化活性を増強する食品組成物。
(11)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、NF-κB転写活性を増強する食品組成物。
(12)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、Toll様受容体を介する活性を増強する食品組成物。
(13)Toll様受容体がToll様受容体9である、(12)に記載の食品組成物。
(14)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドがLactobacillus gasseri OLL2716由来のオリゴヌクレオチドである、(9)〜(13)のいずれかに記載の食品組成物。
(15)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドが、配列番号:1〜28のいずれかに記載の配列からなる、(9)〜(14)のいずれかに記載の食品組成物。
(16)ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドが、配列番号:1、2、7、9、11、15、21、22、24、または26のいずれかに記載の配列からなる、(9)〜(14)のいずれかに記載の食品組成物。
本発明は、ATコア配列5'-ATTTTTAC-3' または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、食品組成物に関する。
本発明の薬剤、食品組成物は、前記特定のオリゴヌクレオチドを含んでいれば良く、例えば医薬上許容される賦形剤等の添加物や食品用の添加物を添加して用いることが出来、その剤型は、固体状、液状であっても良い。投与経路が経口摂取の場合、その使用量は症状、年令、体重、投与方法および剤形等によって異なる。
以下の方法によって、ブタ由来免疫細胞(ブタパイエル板細胞、ブタ脾臓細胞)およびヒト末梢血単核球細胞の調製を行った。
成熟ブタより脾臓組織および腸管組織を摘出し、腸管についてはパイエル板組織を単離して、-PBS(pH7.5,penicillin-streptomycin含)で洗浄後、メッシュ上ですりつぶして細胞を回収した。細胞はRPMI1640 complete medium (10%FCS,penicillin -streptomycin含)に懸濁し、1500rpm×5minにて3回遠心洗浄した。最後にセルストレイナーに通し濾過後、細胞懸濁液を氷上に置いた。
成人男性より採血した静脈血をHISTOPAQUE-1077(Sigma-Aldrich)に重層し、濃度勾配遠心分離によりPBMCを採取した。最後にセルストレイナーに通して、細胞懸濁液を氷上に置いた。
下記の方法によって、ブタパイエル板細胞、ブタ脾臓細胞、およびヒト末梢血単核球細胞を用いて、リンパ球幼若化活性試験を行った。
96well plate に100μM に調製したオリゴヌクレオチドを1検体につき10μLずつ3wellに播き、その上から、〔実施例1〕で調製した細胞を90μL (2×105個/well)ずつ播き、32時間インキュベート(37℃, 5%CO2)した。
Methyl-[3H]-Uridineを9.25kBq/wellとなるように添加し、16時間パルスラベルした。
インキュベート(37℃、5%CO2)終了後、セルハーベスターにより細胞をラボメッシュフィルターに回収しよく乾燥させた。
専用バイアルに移し、液体シンチレーター用カクテルを加え、液体シンチレーションカウンターにより細胞に取り込まれたMethyl-[3H]-Uridine量を測定した。
まず、ブタパイエル板細胞を用いてリンパ球幼若化活性試験を5回行い、SI値が1.0以上の上位113種を選抜した(図1)。次に、ブタ脾臓細胞を用いて,選抜した113種のオリゴヌクレオチドで刺激した時のリンパ球幼若化活性試験からSI値が1.4以上の上位28種を選抜した (図2)。さらに、選抜した28種のオリゴヌクレオチドについて,ヒト末梢血単核球細胞を用いて、リンパ球幼若化活性試験を行い,活性の再現性ならびにヒト免疫細胞に対する効果について検討した結果、全てについてSI値が1.5以上で有意な活性が得られた (図3)。
LG114 : ATTGTCATTTTTACCATAGT (配列番号:1)
LG127 : CATGGTATTTTTACAATAGA (配列番号:2)
LG140 : CCGAGCATTTTTACTGCTTA (配列番号:3)
LG147 : CTATTCATTTTTACCAAATT (配列番号:4)
LG150 : CTCACGATTTTTACCGCACA (配列番号:5)
LG171 : GACTTTATTTTTACCGGCGA (配列番号:6)
LG172 : GAGTATATTTTTACAATATG (配列番号:7)
LG174 : GAGTATATTTTTACCGTTGA (配列番号:8)
LG175 : GATAAAATTTTTACCAATGA (配列番号:9)
LG178 : GCAATAATTTTTACATCATA (配列番号:10)
LG179 : GCAATAATTTTTACCAACTA (配列番号:11)
LG180 : GCATTTATTTTTACGAAATT (配列番号:12)
LG181 : GCCCATATTTTTACGATGAG (配列番号:13)
LG182 : GCGGGTATTTTTACTCTTAT (配列番号:14)
LG186 : GCTGGCATTTTTACCTTAAG (配列番号:15)
LG187 : GCTGGTATTTTTACGGGATT (配列番号:16)
LG190 : GGAAAAATTTTTACTAAATC (配列番号:17)
LG284 : TGAAATATTTTTACGATTAC (配列番号:18)
LG289 : TGAGCCATTTTTACCGATTA (配列番号:19)
LG297 : TGGAATATTTTTACCAACAA (配列番号:20)
LG301 : TGGTTGATTTTTACATGAAA (配列番号:21)
LG310 : TTAACAATTTTTACCCAAGA (配列番号:22)
LG359 : TTTTTTATTTTTACGTTGAT (配列番号:23)
LG360 : TTTTTTATTTTTACTATTAT (配列番号:24)
LGe01 : AATAATTTATTATATTGTTC (配列番号:25)
LGe02 : ACACTTTTATTATATAGCAC (配列番号:26)
LGe11 : GTTAGTTTATTATATATGGC (配列番号:27)
LGe14 : TGATTTTTATTATATTGGTG (配列番号:28)
以下の方法により、ブタTLR9トランスフェクタント(T. Shimosato, H. Kitazawa, S. Katoh, Y. Tomioka, R. Karima, S. Ueha, Y. Kawai, T. Hishinuma, K. Matsushima, T. Saito: Biochim. Biophys. Acta., 1627, 56 (2003)、T. Shimosato, H. Kitazawa, M. Tohno, S. Katoh, Y. Kawai, T. Saito. Anim. Sci. J. 75,377 (2004))を用いて、NF-κB転写活性試験を行った。
ハムスター卵巣細胞(CHOK-1 cells)にブタTLR9遺伝子をトランスフェクションし、遺伝子を強制発現させた細胞株(CHOK-1sTLR9 trans) を4×104個ずつ24wellプレートdishに播き、37℃、5%CO2下で一晩培養した。
リポフェクション法によりヒトNF-κB転写レポーターベクター(pGLM-ENH luci vector:1μg)をトランスフェクションし、6時間後にPBSで洗浄後、-FCS DMEM培地に置き換えた。24時間インキュベート後、各種オリゴヌクレオチドを3wellごと1μMで刺激した。刺激開始から24時間後にPBSで洗浄し、細胞を溶解後回収し、15,000rpm×5min、4℃遠心し上清のみを回収した。
細胞溶解液にルシフェリンを添加した直後2sec〜10secまでの発光変化についてプレートルミノメーター(MicroLumat LB96V)を用いて測定し、発光強度をNF-κB mRNA転写活性として評価した。
リンパ球幼若化活性試験およびNF-κB転写活性試験より得られたデータ数値からTTEST、標準偏差を算出し、controlを1.0とした場合の刺激係数(Stimulation Index (SI))としてグラフ化した。
Claims (16)
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、免疫応答を増強する薬剤。
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、リンパ球幼若化活性を増強する薬剤。
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、NF-κB転写活性を増強する薬剤。
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、Toll様受容体を介する活性を増強する薬剤。
- Toll様受容体がToll様受容体9である、請求項4に記載の薬剤。
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドがLactobacillus gasseri OLL2716由来のオリゴヌクレオチドである、請求項1〜5のいずれかに記載の薬剤。
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドが、配列番号:1〜28のいずれかに記載の配列からなる、請求項1〜6のいずれかに記載の薬剤
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドが、配列番号:1、2、7、9、11、15、21、22、24、または26のいずれかに記載の配列からなる、請求項1〜6のいずれかに記載の薬剤。
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、免疫応答を増強する食品組成物。
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、リンパ球幼若化活性を増強する食品組成物。
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、NF-κB転写活性を増強する食品組成物。
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドを有効成分とする、Toll様受容体を介する活性を増強する食品組成物。
- Toll様受容体がToll様受容体9である、請求項12に記載の食品組成物。
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドがLactobacillus gasseri OLL2716由来のオリゴヌクレオチドである、請求項9〜13のいずれかに記載の食品組成物。
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドが、配列番号:1〜28のいずれかに記載の配列からなる、請求項9〜14のいずれかに記載の食品組成物。
- ATコア配列5'-ATTTTTAC-3'または5'-TTTATTATAT-3'を有するオリゴヌクレオチドが、配列番号:1、2、7、9、11、15、21、22、24、または26のいずれかに記載の配列からなる、請求項9〜14のいずれかに記載の食品組成物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005053998A JP5403457B2 (ja) | 2005-02-28 | 2005-02-28 | Atオリゴヌクレオチドを有効成分とする免疫応答増強性薬剤及び食品組成物 |
PCT/JP2006/303688 WO2006093118A1 (ja) | 2005-02-28 | 2006-02-28 | Atオリゴヌクレオチドを有効成分とする免疫応答増強性薬剤及び食品組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005053998A JP5403457B2 (ja) | 2005-02-28 | 2005-02-28 | Atオリゴヌクレオチドを有効成分とする免疫応答増強性薬剤及び食品組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006232790A true JP2006232790A (ja) | 2006-09-07 |
JP5403457B2 JP5403457B2 (ja) | 2014-01-29 |
Family
ID=36941147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005053998A Active JP5403457B2 (ja) | 2005-02-28 | 2005-02-28 | Atオリゴヌクレオチドを有効成分とする免疫応答増強性薬剤及び食品組成物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5403457B2 (ja) |
WO (1) | WO2006093118A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009005124A1 (ja) * | 2007-07-04 | 2009-01-08 | Kikkoman Corporation | 乳酸菌由来の2本鎖rna |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7088821B2 (ja) * | 2018-12-21 | 2022-06-21 | トヨタ自動車株式会社 | 充電処理システム |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003510282A (ja) * | 1999-09-25 | 2003-03-18 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 免疫刺激核酸 |
JP2005522202A (ja) * | 2002-04-12 | 2005-07-28 | 明治乳業株式会社 | Helicobacterpylori除菌性チーズ |
-
2005
- 2005-02-28 JP JP2005053998A patent/JP5403457B2/ja active Active
-
2006
- 2006-02-28 WO PCT/JP2006/303688 patent/WO2006093118A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003510282A (ja) * | 1999-09-25 | 2003-03-18 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 免疫刺激核酸 |
JP2005522202A (ja) * | 2002-04-12 | 2005-07-28 | 明治乳業株式会社 | Helicobacterpylori除菌性チーズ |
Non-Patent Citations (3)
Title |
---|
JPN6011048665; International Journal of Food Microbiology 65, 2001, 149-162 * |
JPN6012036268; 'Lactobacillus gasseriOLL2716 (LG21)含有ヨーグルトの摂取がHelicobacter pylori陽性者の胃内H.pylori菌数' 月刊フードケミカル 7, 2001, 31-34 * |
JPN7011003385; Biochemical and Biophysical Research Communications No.326, 2005, 782-787 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009005124A1 (ja) * | 2007-07-04 | 2009-01-08 | Kikkoman Corporation | 乳酸菌由来の2本鎖rna |
JPWO2009005124A1 (ja) * | 2007-07-04 | 2010-08-26 | キッコーマン株式会社 | 乳酸菌由来の2本鎖rna |
US8334371B2 (en) | 2007-07-04 | 2012-12-18 | Kikkoman Corporation | Lactic acid bacteria-derived double-stranded RNA |
JP5099649B2 (ja) * | 2007-07-04 | 2012-12-19 | キッコーマン株式会社 | 乳酸菌由来の2本鎖rna |
Also Published As
Publication number | Publication date |
---|---|
WO2006093118A1 (ja) | 2006-09-08 |
JP5403457B2 (ja) | 2014-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11944657B2 (en) | Agent for inducing interferon production containing lactic acid bacteria | |
US11759486B2 (en) | Lactobacillus plantarum and composition comprising same | |
US9801914B2 (en) | Prevotella histicola preparations and the treatment of autoimmune conditions | |
JP5172151B2 (ja) | コンパニオンアニマルのためのプロバイオティクビフィズス菌の使用方法 | |
KR101312745B1 (ko) | 면역기능 조정제 | |
JP5718916B2 (ja) | 新規なラクトバチルス・プランタラム及びこれを含む組成物 | |
KR101614262B1 (ko) | 신규 유산균, 그리고 신규 유산균을 함유하는 의약, 음식품 및 사료 | |
JP2012510291A (ja) | 新規なラクトバチルス・プランタラム及びこれを含む組成物 | |
US20110269165A1 (en) | Lactic acid bacteria and their cellular components inducing immunoregulatory function, and method of obtaining the same | |
JP6531893B2 (ja) | 濾胞性ヘルパーt細胞増加剤 | |
JP5403457B2 (ja) | Atオリゴヌクレオチドを有効成分とする免疫応答増強性薬剤及び食品組成物 | |
AU2015268629A1 (en) | Interferon production-inducing agent containing lactic acid bacteria | |
WO2023100745A1 (ja) | 免疫賦活化組成物 | |
US20240226194A1 (en) | Agent for inducing interferon production containing lactic acid bacteria | |
WO2024100755A1 (ja) | 腸管バリア機能向上用及び腸管上皮タイトジャンクション増強用組成物 | |
JP2007091704A (ja) | IgE産生抑制剤、IgE産生抑制用飲食品、抗アレルギー剤および抗アレルギー用飲食品 | |
Ming et al. | Research & Reviews: Journal of Microbiology and Biotechnology | |
WO2005058355A1 (en) | Immune stimulation by administration of bacteria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071105 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120711 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120822 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130501 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130521 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131016 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131018 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5403457 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |